When is EvolutionaryScale the better choice?

The models are published at the highest level, with the flagship model appearing in a major peer reviewed journal, so the method has passed external review rather than a demonstration. The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely for an organisation that cannot rely on a vendor remaining available. The strongest governance disclosure located in this category, addressing the specific biosecurity risk that protein design creates rather than publishing generic principles.

When is Profluent the better choice?

Peer reviewed twice at the highest level and specific about architecture, with the foundational demonstration that language models can generate functional proteins published in a major journal. Molecular evidence is unusually direct, including designed systems validated experimentally rather than only benchmarked computationally. Three access routes are named openly, from licensing a designed molecule through to platform access, which makes the commercial structure legible even without a published price.

EvolutionaryScale vs Profluent

Last VerifiedAugust 4, 2026

Verdict

The two protein language model labs with the strongest publication records, descended from different research lineages, and both have done the thing this category usually skips: submitted the method to peer review at the highest level. EvolutionaryScale came out of the group that built the first transformer language model for proteins and its flagship model reasons over sequence, structure and function together. Profluent came out of the project that first demonstrated language models could generate functional proteins. The differentiators are access and governance. EvolutionaryScale offers the widest access routes in this category including holding the weights yourself, and publishes the most substantive position anywhere here on the biosecurity risk that designing novel proteins creates. Profluent is more legible commercially, with three named routes from licensing a molecule to platform access, and has not addressed the biosecurity question equivalently.

Select EvolutionaryScale if

The models are published at the highest level, with the flagship model appearing in a major peer reviewed journal, so the method has passed external review rather than a demonstration.
The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely for an organisation that cannot rely on a vendor remaining available.
The strongest governance disclosure located in this category, addressing the specific biosecurity risk that protein design creates rather than publishing generic principles.

Select Profluent if

Peer reviewed twice at the highest level and specific about architecture, with the foundational demonstration that language models can generate functional proteins published in a major journal.
Molecular evidence is unusually direct, including designed systems validated experimentally rather than only benchmarked computationally.
Three access routes are named openly, from licensing a designed molecule through to platform access, which makes the commercial structure legible even without a published price.

Attribute Matrix

Side by Side

Axis	E EvolutionaryScale	P Profluent
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.

Atomwise vs Schrödinger→BenevolentAI vs insitro→Chai Discovery vs Cradle→Genesis Molecular AI vs Iktos→Iambic Therapeutics vs Relay Therapeutics→Insilico Medicine vs Recursion→

Disclosure

Both companies design proteins that do not exist in nature, which is the one place in this index where the governance question is biosecurity rather than bias. EvolutionaryScale publishes a substantive position on that risk; Profluent's disclosure gap on it is specific and consequential and should be raised directly in any evaluation. Neither holds a located security attestation or trust centre.

Molecular evidence and clinical evidence are different things on both records: excellent laboratory validation exists and no therapeutic from either has been established in humans, so neither should be evaluated as a clinical stage proposition.